{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:44:45Z","timestamp":1792788285616,"version":"4.5.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,7,5]],"date-time":"2018-07-05T00:00:00Z","timestamp":1530748800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"ArmaGen, Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13023-018-0849-8","type":"journal-article","created":{"date-parts":[[2018,7,5]],"date-time":"2018-07-05T09:31:58Z","timestamp":1530783118000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":132,"title":["Neurocognitive and somatic stabilization in pediatric patients with severe Mucopolysaccharidosis Type I after 52 weeks of intravenous brain-penetrating insulin receptor antibody-iduronidase fusion protein (valanafusp alpha): an open label phase 1-2 trial"],"prefix":"10.1186","volume":"13","author":[{"given":"Roberto","family":"Giugliani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciana","family":"Giugliani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiano","family":"de Oliveira Poswar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karina Carvalho","family":"Donis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amauri Dalla","family":"Corte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben J.","family":"Boado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Nestrasil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2664-1338","authenticated-orcid":false,"given":"William M.","family":"Pardridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,7,5]]},"reference":[{"issue":"3","key":"849_CR1","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1056\/NEJM200101183440304","volume":"344","author":"ED Kakkis","year":"2001","unstructured":"Kakkis ED, Muenzer J, Tiller GE, Waber L, Belmont J, Passage M, et al. Enzyme-replacement therapy in mucopolysaccharidosis I. N Engl J Med. 2001;344(3):182\u20138.","journal-title":"N Engl J Med."},{"issue":"5","key":"849_CR2","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.jpeds.2004.01.046","volume":"144","author":"JE Wraith","year":"2004","unstructured":"Wraith JE, Clarke LA, Beck M, Kolodny EH, Pastores GM, Muenzer J, et al. Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase). J Pediatr. 2004;144(5):581\u20138.","journal-title":"J Pediatr."},{"issue":"1","key":"849_CR3","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.ymgme.2007.01.011","volume":"91","author":"GM Pastores","year":"2007","unstructured":"Pastores GM, Arn P, Beck M, Clarke JT, Guffon N, Kaplan P, et al. The MPS I registry: design, methodology, and early findings of a global disease registry for monitoring patients with Mucopolysaccharidosis Type I. Mol Genet Metab. 2007;91(1):37\u201347.","journal-title":"Mol Genet Metab."},{"issue":"1","key":"849_CR4","doi-asserted-by":"publisher","first-page":"e37","DOI":"10.1542\/peds.2006-2156","volume":"120","author":"JE Wraith","year":"2007","unstructured":"Wraith JE, Beck M, Lane R, van der Ploeg A, Shapiro E, Xue Y, et al. Enzyme replacement therapy in patients who have mucopolysaccharidosis I and are younger than 5 years: results of a multinational study of recombinant human alpha-L-iduronidase (laronidase). Pediatrics. 2007;120(1):e37\u201346.","journal-title":"Pediatrics."},{"issue":"4","key":"849_CR5","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1021\/acs.molpharmaceut.6b01166","volume":"14","author":"RJ Boado","year":"2017","unstructured":"Boado RJ, Pardridge WM. Brain and Organ Uptake in the Rhesus Monkey in Vivo of Recombinant Iduronidase Compared to an Insulin Receptor Antibody-Iduronidase Fusion Protein. Mol Pharm. 2017;14(4):1271\u20137.","journal-title":"Mol Pharm."},{"issue":"13","key":"849_CR6","doi-asserted-by":"publisher","first-page":"2164","DOI":"10.1182\/blood-2014-11-608075","volume":"125","author":"M Aldenhoven","year":"2015","unstructured":"Aldenhoven M, Wynn RF, Orchard PJ, O'Meara A, Veys P, Fischer A, et al. Long-term outcome of Hurler syndrome patients after hematopoietic cell transplantation: an international multicenter study. Blood. 2015;125(13):2164\u201372.","journal-title":"Blood."},{"key":"849_CR7","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/8904_2015_521","volume":"29","author":"AS Kunin-Batson","year":"2016","unstructured":"Kunin-Batson AS, Shapiro EG, Rudser KD, Lavery CA, Bjoraker KJ, Jones SA, et al. Long-Term Cognitive and Functional Outcomes in Children with Mucopolysaccharidosis (MPS)-IH (Hurler Syndrome) Treated with Hematopoietic Cell Transplantation. JIMD Rep. 2016;29:95\u2013102.","journal-title":"JIMD Rep."},{"issue":"2","key":"849_CR8","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1002\/bit.21602","volume":"99","author":"RJ Boado","year":"2008","unstructured":"Boado RJ, Zhang Y, Zhang Y, Xia CF, Wang Y, Pardridge WM. Genetic engineering of a lysosomal enzyme fusion protein for targeted delivery across the human blood-brain barrier. Biotechnol Bioeng. 2008;99(2):475\u201384.","journal-title":"Biotechnol Bioeng."},{"issue":"2","key":"849_CR9","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.jbiotec.2009.08.019","volume":"144","author":"RJ Boado","year":"2009","unstructured":"Boado RJ, Hui EK, Lu JZ, Pardridge WM. AGT-181: expression in CHO cells and pharmacokinetics, safety, and plasma iduronidase enzyme activity in Rhesus monkeys. J Biotechnol. 2009;144(2):135\u201341.","journal-title":"J Biotechnol."},{"issue":"4","key":"849_CR10","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1021\/mp200136x","volume":"8","author":"RJ Boado","year":"2011","unstructured":"Boado RJ, Hui EK, Lu JZ, Zhou QH, Pardridge WM. Reversal of lysosomal storage in brain of adult MPS-I mice with intravenous Trojan horse-iduronidase fusion protein. Mol Pharm. 2011;8(4):1342\u201350.","journal-title":"Mol Pharm."},{"key":"849_CR11","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s40259-018-0264-7","volume":"32","author":"WM Pardridge","year":"2018","unstructured":"Pardridge WM, Boado RJ, Giugliani R, Schmidt M. Plasma Pharmacokinetics of Valanafusp Alpha, a Human Insulin Receptor Antibody-Iduronidase Fusion Protein, in Patients with Mucopolysaccharidosis Type I. BioDrugs. 2018;32:169\u201376.","journal-title":"BioDrugs."},{"issue":"1","key":"849_CR12","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1021\/bc3005123","volume":"24","author":"RJ Boado","year":"2013","unstructured":"Boado RJ, Hui EK, Lu JZ, Pardridge WM. IgG-enzyme fusion protein: pharmacokinetics and anti-drug antibody response in rhesus monkeys. Bioconjug Chem. 2013;24(1):97\u2013104.","journal-title":"Bioconjug Chem."},{"issue":"4","key":"849_CR13","doi-asserted-by":"publisher","first-page":"e1035","DOI":"10.1542\/peds.2009-3432","volume":"127","author":"MJ Dickerman","year":"2011","unstructured":"Dickerman MJ, Jacobs BR, Vinodrao H, Stockwell DC. Recognizing hypoglycemia in children through automated adverse-event detection. Pediatrics. 2011;127(4):e1035\u201341.","journal-title":"Pediatrics."},{"issue":"2","key":"849_CR14","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ymgme.2017.05.004","volume":"121","author":"JH van der Lee","year":"2017","unstructured":"van der Lee JH, Morton J, Adams HR, Clarke L, Ebbink BJ, Escolar ML, et al. Cognitive endpoints for therapy development for neuronopathic mucopolysaccharidoses: Results of a consensus procedure. Mol Genet Metab. 2017;121(2):70\u20139.","journal-title":"Mol Genet Metab."},{"issue":"2","key":"849_CR15","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1021\/acs.molpharmaceut.7b00958","volume":"15","author":"RJ Boado","year":"2018","unstructured":"Boado RJ, Lu JZ, Hui EK, Pardridge WM. Reduction in Brain Heparan Sulfate with Systemic Administration of an IgG Trojan Horse-Sulfamidase Fusion Protein in the Mucopolysaccharidosis Type IIIA Mouse. Mol Pharm. 2018;15(2):602\u20138.","journal-title":"Mol Pharm."},{"key":"849_CR16","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s13023-018-0817-3","volume":"13","author":"EG Shapiro","year":"2018","unstructured":"Shapiro EG, Whitley CB, Eisengart JB. Beneath the floor: re-analysis of neurodevelopmental outcomes in untreated Hurler syndrome. Orphanet J Rare Dis. 2018;13:76.","journal-title":"Orphanet J Rare Dis."},{"issue":"10","key":"849_CR17","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1124\/dmd.112.046375","volume":"40","author":"RJ Boado","year":"2012","unstructured":"Boado RJ, Hui EK, Lu JZ, Pardridge WM. Glycemic control and chronic dosing of rhesus monkeys with a fusion protein of iduronidase and a monoclonal antibody against the human insulin receptor. Drug Metab Dispos. 2012;40(10):2021\u20135.","journal-title":"Drug Metab Dispos."},{"issue":"4","key":"849_CR18","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.ymgme.2016.02.006","volume":"117","author":"Y Xue","year":"2016","unstructured":"Xue Y, Richards SM, Mahmood A, Cox GF. Effect of anti-laronidase antibodies on efficacy and safety of laronidase enzyme replacement therapy for MPS I: A comprehensive meta-analysis of pooled data from multiple studies. Mol Genet Metab. 2016;117(4):419\u201326.","journal-title":"Mol Genet Metab."},{"issue":"1-2","key":"849_CR19","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ymgme.2015.06.002","volume":"116","author":"EG Shapiro","year":"2015","unstructured":"Shapiro EG, Nestrasil I, Rudser K, Delaney K, Kovac V, Ahmed A, et al. Neurocognition across the spectrum of mucopolysaccharidosis type I: Age, severity, and treatment. Mol Genet Metab. 2015;116(1-2):61\u20138.","journal-title":"Mol Genet Metab."},{"issue":"7","key":"849_CR20","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.3174\/ajnr.A2032","volume":"31","author":"Z Fan","year":"2010","unstructured":"Fan Z, Styner M, Muenzer J, Poe M, Escolar M. Correlation of automated volumetric analysis of brain MR imaging with cognitive impairment in a natural history study of mucopolysaccharidosis II AJNR. Am J Neuroradiol. 2010;31(7):1319\u201323.","journal-title":"Am J Neuroradiol"},{"key":"849_CR21","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1373\/clinchem.2010.161141","volume":"57","author":"H Zhang","year":"2011","unstructured":"Zhang H, Young SP, Auray-Blais C, Orchard PJ, Tolar J, et al. Analysis of glycosaminoglycans in cerebrospinal fluid from patients with Mucopolysaccharidosis by isotope-dilution ultra-performance liquid chromatography-tandem mass spectrometry. Clin Chem. 2011;57:1005\u201312.","journal-title":"Clin Chem."},{"key":"849_CR22","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/S1474-4422(17)30169-2","volume":"16","author":"M Tardieu","year":"2017","unstructured":"Tardieu M, Zerah M, Gougeon M-L, Ausseil J, de Bournonville S, et al. Intracerebral gene therapy in children with mucopolysaccharidosis type IIIB syndrome: an uncontrolled phase 1\/2 clinical trial. Lancet Neurol. 2017;16:712\u201320.","journal-title":"Lancet Neurol"},{"issue":"1","key":"849_CR23","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/gim.2015.36","volume":"18","author":"J Muenzer","year":"2016","unstructured":"Muenzer J, Hendriksz CJ, Fan Z, Vijayaraghavan S, Perry V, Santra S, et al. A phase I\/II study of intrathecal idursulfase-IT in children with severe mucopolysaccharidosis II. Genet Med. 2016;18(1):73\u201381.","journal-title":"Genet Med."},{"issue":"3","key":"849_CR24","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.ymgme.2016.05.006","volume":"118","author":"SA Jones","year":"2016","unstructured":"Jones SA, Breen C, Heap F, Rust S, de Ruijter J, Tump E, et al. A phase 1\/2 study of intrathecal heparan-N-sulfatase in patients with mucopolysaccharidosis IIIA. Mol Genet Metab. 2016;118(3):198\u2013205.","journal-title":"Mol Genet Metab."},{"issue":"1","key":"849_CR25","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/pr.2011.13","volume":"71","author":"D Auclair","year":"2012","unstructured":"Auclair D, Finnie J, Walkley SU, White J, Nielsen T, Fuller M, et al. Intrathecal recombinant human 4-sulfatase reduces accumulation of glycosaminoglycans in dura of mucopolysaccharidosis VI cats. Pediatr Res. 2012;71(1):39\u201345.","journal-title":"Pediatr Res."},{"issue":"9","key":"849_CR26","doi-asserted-by":"publisher","first-page":"3241","DOI":"10.1021\/acs.molpharmaceut.6b00456","volume":"13","author":"RJ Boado","year":"2016","unstructured":"Boado RJ, Hui EK, Lu JZ, Pardridge WM. Very High Plasma Concentrations of a Monoclonal Antibody against the Human Insulin Receptor Are Produced by Subcutaneous Injection in the Rhesus Monkey. Mol Pharm. 2016;13(9):3241\u20136.","journal-title":"Mol Pharm."},{"issue":"1","key":"849_CR27","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.ymgme.2008.10.009","volume":"96","author":"R Giugliani","year":"2009","unstructured":"Giugliani R, Rojas VM, Martins AM, Valadares ER, Clarke JT, Goes JE, et al. A dose-optimization trial of laronidase (Aldurazyme) in patients with mucopolysaccharidosis I. Mol Genet Metab. 2009;96(1):13\u20139.","journal-title":"Mol Genet Metab."},{"issue":"2","key":"849_CR28","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1097\/GIM.0b013e3181fea459","volume":"13","author":"J Muenzer","year":"2011","unstructured":"Muenzer J, Beck M, Eng CM, Giugliani R, Harmatz P, Martin R, et al. Long-term, open-labeled extension study of idursulfase in the treatment of Hunter syndrome. Genet Med. 2011;13(2):95\u2013101.","journal-title":"Genet Med."}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-018-0849-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13023-018-0849-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-018-0849-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,4]],"date-time":"2019-07-04T19:06:44Z","timestamp":1562267204000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-018-0849-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,5]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["849"],"URL":"https:\/\/doi.org\/10.1186\/s13023-018-0849-8","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,5]]},"assertion":[{"value":"3 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All patients were treated and evaluated at the HCPA-Hospital das Clinical de Porto Alegre, Brazil. The clinical protocol was reviewed and approved by the local Institutional Review Board, the National Ethics Committee (CONEP) and the National Health Surveillance Agency (ANVISA) in Brazil. Written informed consent was read, understood, and signed by a parent or guardian before each patient enrolled in the study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MS and RJB are employees of ArmaGen, and RG, IN, SC, and WMP have received consulting fees from ArmaGen. The other authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"110"}}